The Trump administration is set to announce tariffs as soon as Thursday on drugmakers that haven’t struck deals guaranteeing low prices in the US, according to sources https://t.co/qMTA8crxhZ ...

Core Viewpoint - Coherus Oncology (CHRS) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for near-term stock price movements [2][4]. - Rising earnings estimates for Coherus Oncology indicate an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Coherus Oncology to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [9][10]. Earnings Estimate Revisions - For the fiscal year ending December 2026, Coherus Oncology is expected to earn -$0.23 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 9.6% over the past three months [8].

Core Insights - Abbott Laboratories (ABT) has a market capitalization of $181.2 billion and operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices [1] Earnings Expectations - Analysts anticipate Abbott's Q1 2026 earnings per share (EPS) to be $1.15 on a diluted basis, reflecting a 5.5% increase from $1.09 in the same quarter last year [2] - For fiscal 2026, the projected EPS is $5.68, which represents a 10.3% increase from $5.15 in fiscal 2025, with further growth expected to $6.24 in fiscal 2027, marking a year-over-year increase of approximately 9.9% [3] Earnings History - Abbott's reported EPS for the last four quarters were as follows: $1.09, $1.26, $1.30, and $1.50, with the company consistently meeting or exceeding Wall Street's EPS estimates [4] Stock Performance - Over the past 52 weeks, ABT stock has declined by 16.9%, underperforming the S&P 500 Index, which rose by 13.7% during the same period [5] - Following the release of mixed Q4 2025 earnings, ABT stock fell nearly 10%, despite an adjusted EPS of $1.50 that surpassed estimates [6] Analyst Ratings - Analysts maintain a "Strong Buy" rating for ABT, with 20 out of 28 analysts recommending a "Strong Buy," while two suggest a "Moderate Buy," and six advise a "Hold" [7] - The average analyst price target for ABT is $134.21, indicating a potential upside of 29% from current levels [7]

分组1 - Sanara MedTech Inc. reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share, compared to a loss of $0.18 per share a year ago, representing an earnings surprise of -63.64% [1] - The company posted revenues of $27.55 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.53%, and compared to year-ago revenues of $26.31 million [2] - Sanara MedTech shares have lost about 21.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.13 on $27.9 million in revenues, and for the current fiscal year, it is $0.65 on $118.6 million in revenues [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 33% of over 250 Zacks industries, indicating that the industry outlook can materially impact stock performance [8]

The drugs are being sought out by healthy people in the hope that they will help preserve that health for longer, and even extend life. Does the science bear that out? https://t.co/UvbQJAMJgB ...

Core Viewpoint - Cardinal Health stock is currently in a buy zone, maintaining stability amid macroeconomic challenges such as the U.S.-Israeli war and drug pricing negotiations [1] Financial Performance - In the fiscal second quarter, Cardinal Health reported a 19% increase in pharmaceutical and specialty solutions sales, totaling $60.7 billion [1] - The global medical products and distribution unit generated $3.3 billion in sales, reflecting a 3% increase [1] - The "other" segment, which includes at-home solutions and nuclear/precision health solutions, saw a significant 34% year-over-year growth, generating $1.7 billion [1] Market Position and Analyst Sentiment - Cardinal Health is recognized as one of the top three medical wholesalers in the U.S., alongside McKesson and Cencora [1] - Analysts have given positive reviews, noting strong demand and effective execution across all business segments, with double-digit profit growth reported [1] - The company is expanding into specialty drugs and has made acquisitions to enhance its capabilities in this area [1] Stock Performance and Technical Indicators - Cardinal Health stock has a strong IBD Digital Relative Strength Rating of 91 out of 99, indicating robust performance compared to other stocks [1] - The stock has a Composite Rating of 94, placing it in the top 6% of all stocks across industries [1] - The stock remains above its 50-day and 200-day moving averages, indicating a favorable technical position [1]

Company Performance - Novo Nordisk's stock price decreased by 2.09% to $38.02, underperforming the S&P 500's daily loss of 1.52% [1] - Over the past month, shares have depreciated by 20.33%, significantly worse than the Medical sector's loss of 3.1% and the S&P 500's loss of 2.25% [1] Financial Projections - The upcoming earnings per share (EPS) for Novo Nordisk is projected at $0.86, indicating a 6.52% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $11.23 billion, reflecting a 1.99% increase from the previous year [2] - For the full year, projected earnings are $3.33 per share and revenue is $43.91 billion, representing declines of 15.91% and 6.13% respectively from the prior year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Novo Nordisk are crucial for investors, as positive revisions can indicate a favorable business outlook [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Novo Nordisk at 4 (Sell), with the EPS estimate moving 0.36% lower over the past month [5] Valuation Metrics - Novo Nordisk's Forward P/E ratio is 11.68, which is lower than the industry average Forward P/E of 15.66 [6] - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 205, placing it in the bottom 17% of over 250 industries [6]

Core Viewpoint - Hims & Hers is currently engaged in a dispute with Novo Nordisk, but the long-term outlook for the company remains positive due to its innovative direct-to-consumer model and significant growth potential [1][11]. Company Overview - Hims & Hers operates as a direct-to-consumer drug company, utilizing a digital platform to engage customers through a lifestyle approach [2]. - The company has seen substantial growth in its subscriber base, increasing from approximately 300,000 at the end of 2020 to a projected 2.5 million by the end of 2025 [4]. Subscriber Growth and Revenue Model - In 2025, Hims & Hers added over 280,000 new subscribers, creating an annuity-like income stream through ongoing subscriptions [5]. - The growing customer base not only supports current revenue but also lays the groundwork for future expansion as subscribers tend to purchase multiple products [4][5]. Expansion Strategy - Hims & Hers aims to broaden its product offerings, which could lead to a significant increase in revenues as the brand gains traction in the consumer market [6]. Market Position and Financial Metrics - The current market capitalization of Hims & Hers is approximately $3.6 billion, with a price-to-earnings ratio of around 29x, indicating a high valuation that may deter value-oriented investors [7][9]. - The company's gross margin stands at 60.86%, reflecting its profitability [9]. Competitive Landscape - Hims & Hers is facing pushback from Novo Nordisk, which is suing the company to stop the sales of its copycat versions of GLP-1 drugs, a situation that may pose short-term challenges [10][11]. - Despite the competitive pressures, the direct-sales approach of Hims & Hers is resonating well with its subscribers, indicating a strong growth opportunity [11].

Core Insights - Grifols reported a net profit of 402 million euros ($473.96 million) for 2025, more than double the previous year's profit, driven by revenues of 7.5 billion euros, which increased by 7% year-over-year [1][1][1] - Adjusted EBITDA rose to 1.8 billion euros, aligning with market expectations [1][1][1] - The company has experienced a 25% decline in market value since January 2024 due to allegations from Gotham City Research regarding overstated earnings and understated debt, which Grifols has denied and is currently suing the fund [1][1][1]

Core Insights - Novartis is a major Swiss drug company with a market capitalization exceeding $300 billion, focusing on various therapeutic areas including oncology, immunology, neuroscience, and more [1][2] - The company has a strong operational history and diversified business model, making it an attractive option for conservative investors [1][2] Financial Performance - Novartis currently offers a dividend yield of 2.9%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7% [3] - The dividend has been increasing over the past 20 years, with a payout ratio around 45%, indicating a conservative dividend profile [4] Market Challenges - The pharmaceutical industry is highly competitive and technical, with drugs facing limited patent protection, leading to revenue challenges as older drugs lose market share to generics [5] - Despite these challenges, Novartis has identified five drugs in its pipeline that are advancing or gaining new indications, which may help offset future revenue losses from patent expirations [6] Investment Perspective - Novartis is positioned as a core holding for conservative dividend investors, focusing on building a sustainable business rather than seeking high volatility [7]